Do antiangiogenic protein fragments have amyloid properties?
Tumor growth requires proteolytic activity. As a consequence, protein breakdown products are present in the circulation of patients with cancer. Within the past decade a large number of proteolytic fragments have been identified that inhibit angiogenesis and tumor growth. The mechanism of action of these inhibitors is still poorly understood. We recently found that the effects of the angiogenesis inhibitor endostatin on endothelial cells is critically dependent on the presence of cross-beta structure, a structure also present in amyloidogenic polypeptides in plaques of patients with amyloidosis, such as Alzheimer disease. We also showed that cross-beta structure containing endostatin is a ligand for tissue-type plasminogen activator (tPA). We noted that many angiogenesis inhibitors stimulate tPA-mediated plasminogen activation. Because the presence of cross-beta structure is the common denominator in tPA-binding ligands, we hypothesize that these endogenous antiangiogenic proteolytic fragments share features with amyloidogenic polypeptides. We postulate that the cross-beta structural fold is present in these antiangiogenic polypeptide fragments and that this structure mediates the inhibitory effects. The hypothesis provides new insights in the potential mechanisms of these angiogenesis inhibitors and offers opportunities to improve their use.
Gebbink
Martijn F B G
MF
Labortory of Thrombosis and Hemostasis, Department of Hematology, G03.647, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. m.gebbink@azu.nl
Voest
Emile E
EE
Reijerkerk
Arie
A
D000682:Amyloid / Q000737:chemistry*; D020533:Angiogenesis Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity; D000818:Animals; D006801:Humans; D010446:Peptide Fragments / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity; D011487:Protein Conformation; D017510:Protein Folding; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D000682:Amyloid; D020533:Angiogenesis Inhibitors; D010446:Peptide Fragments; D010959:Tissue Plasminogen Activator